Skip to main content

Table 2 Characteristics of 1568 men entering the trial

From: Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]

Characteristic

Values

Age (average years [range])

68.6 (35–92)

Smoking (n [%])

 

   Current

593 (37.8)

   Ex

908 (57.9)

   Never

67 (4.3)

Previous history (n [%])*

 

   Myocardial infarction

332 (21.2)

   Stroke

194 (12.4)

   Stable angina

382 (24.4)

Blood pressure, mmHg (mean [SD])

 

   Systolic

147.5 (21.7)

   Diastolic

77.1 (11.5)

†Diabetes (n [%])

268 (17.1)

‡Antiplatelet medication (n [%])

1027 (65.5)

Fibrinogen, g/l (mean [SD])

3.37 (0.60)

Total cholesterol, mmol/l (mean [SD])

5.64 (0.93)

LDL-cholesterol, mmol/l (mean [SD])

3.40 (0.86)

HDL-cholesterol, mmol/l (mean [SD])

1.19 (0.36)

Triglycerides, mmol/l (mean [SD])

2.40 (1.23)

  1. *Some men with more than one condition. †Insulin (24%), oral therapy (57%) and diet only (22%). ‡Aspirin (95%) and dipyridamole (5%).